Antioxidant, anti-inflammatory and epigenetic potential of curcumin in Alzheimer's disease.
Alzheimer's disease
curcumin
epigenetic regulation
neuroinflammation
oxidative stress
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
16 Jan 2024
16 Jan 2024
Historique:
received:
21
06
2023
accepted:
20
12
2023
medline:
16
1
2024
pubmed:
16
1
2024
entrez:
16
1
2024
Statut:
aheadofprint
Résumé
Alzheimer's disease (AD) constitutes a multifactorial neurodegenerative pathology characterized by cognitive deterioration, personality alterations, and behavioral shifts. The ongoing brain impairment process poses significant challenges for therapeutic interventions due to activating multiple neurotoxic pathways. Current pharmacological interventions have shown limited efficacy and are associated with significant side effects. Approaches focusing on the early interference with disease pathways, before activation of broad neurotoxic processes, could be promising to slow down symptomatic progression of the disease. Curcumin-an integral component of traditional medicine in numerous cultures worldwide-has garnered interest as a promising AD treatment. Current research indicates that curcumin may exhibit therapeutic potential in neurodegenerative pathologies, attributed to its potent anti-inflammatory and antioxidant properties. Additionally, curcumin and its derivatives have demonstrated an ability to modulate cellular pathways via epigenetic mechanisms. This article aims to raise awareness of the neuroprotective properties of curcuminoids that could provide therapeutic benefits in AD. The paper provides a comprehensive overview of the neuroprotective efficacy of curcumin against signaling pathways that could be involved in AD and summarizes recent evidence of the biological efficiency of curcumins in vivo.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : King Abdulaziz University
ID : RG-18-130-43
Informations de copyright
© 2024 The Authors. BioFactors published by Wiley Periodicals LLC on behalf of International Union of Biochemistry and Molecular Biology.
Références
2020 Alzheimer's disease facts and figures. Alzheimers Dement J Alzheimers Assoc. 2020;16:391-460. doi:10.1002/alz.12068
Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778-1783.
Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomed. 2019;14:5541-5554.
Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem Toxicol Int J Publ Br Ind Biol Res Assoc. 2015;83:111-124.
Chiu HF, Venkatakrishnan K, Wang CK. The role of nutraceuticals as a complementary therapy against various neurodegenerative diseases: a mini-review. J Tradit Complement Med. 2020;10(5):434-439.
Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, et al. Protective effects of Indian spice curcumin against amyloid-β in Alzheimer's disease. J Alzheimers Dis. 2018;61(3):843-866.
Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem. 2007;102(4):1095-1104.
Hassan FU, Rehman MSU, Khan MS, Ali MA, Javed A, Nawaz A, et al. Curcumin as an alternative epigenetic modulator: mechanism of action and potential effects. Front Genet. 2019;10:514.
Migliore L, Coppedè F. Gene-environment interactions in Alzheimer disease: the emerging role of epigenetics. Nat Rev Neurol. 2022;18(11):643-660.
Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 2001;18(9):685-716.
Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A Review Free Radic Res. 2002;36(12):1307-1313.
Šimić G, Babić Leko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other Tauopathies, and possible neuroprotective strategies. Biomolecules. 2016;6(1):6.
Moss DW, Bates TE. Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci. 2001;13(3):529-538.
Sawikr Y, Yarla NS, Peluso I, Kamal MA, Aliev G, Bishayee A. Neuroinflammation in Alzheimer's disease: the preventive and therapeutic potential of polyphenolic nutraceuticals. Adv Protein Chem Struct Biol. 2017;108:33-57.
Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci [Internet]. 2001;21(21):8370-8377. https://doi.org/10.1523/JNEUROSCI.21-21-08370.2001
Cassidy L, Fernandez F, Johnson JB, Naiker M, Owoola AG, Broszczak DA. Oxidative stress in Alzheimer's disease: a review on emergent natural polyphenolic therapeutics. Complement Ther Med. 2020;49:102294.
Seeman P, Seeman N. Alzheimer's disease: β-amyloid plaque formation in human brain. Synap N Y N. 2011;65(12):1289-1297.
Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol. 2008;4(5):278-286.
Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408(6809):239-247.
Abdul-Rahman T, Dunham A, Huang H, Bukhari SMA, Mehta A, Awuah WA, et al. Chemotherapy induced cardiotoxicity: a state of the art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics. Curr Probl Cardiol [Internet]. 2023;48(4):101591. https://www.sciencedirect.com/science/article/pii/S0146280623000087
Hulbert AJ, Pamplona R, Buffenstein R, Buttemer WA. Life and death: metabolic rate, membrane composition, and life span of animals. Physiol Rev. 2007;87(4):1175-1213.
Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress and Alzheimer's disease. Free Radic Biol Med. 2009;46(9):1241-1249. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673453/
Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci. 2010;2:12.
McEwen BS. Understanding the potency of stressful early life experiences on brain and body function. Metabolism. 2008;57(Suppl 2):S11-S15.
Salim S. Oxidative stress and the central nervous system. J Pharmacol Exp Ther. 2017;360(1):201-205.
Zhang Y, Gao H, Zheng W, Xu H. Current understanding of the interactions between metal ions and apolipoprotein E in Alzheimer's disease. Neurobiol Dis. 2022;172:105824. https://www.sciencedirect.com/science/article/pii/S0969996122002169
Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta. 2007;1768(8):1976-1990.
Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010;59(4-5):290-294.
Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11):863-873. https://www.nature.com/articles/nrn1537
Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998;158(1):47-52.
Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, et al. Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods. 1997;76(1):53-59.
Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci Off J Isfahan Univ Med Sci. 2014;19(2):164-174.
Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012;18(2):291-295.
Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J Neurochem. 2016;139(S1):179-197. https://doi.org/10.1111/jnc.13425
Kontoghiorghes GJ, Kontoghiorghe CN. Iron and chelation in biochemistry and medicine: new approaches to controlling iron metabolism and treating related diseases. Cells. 2020;9(6):1456. https://www.mdpi.com/2073-4409/9/6/1456
Wu Y, Torabi SF, Lake RJ, Hong S, Yu Z, Wu P, et al. Simultaneous Fe2+/Fe3+ imaging shows Fe3+ over Fe2+ enrichment in Alzheimer's disease mouse brain. Sci Adv. 2023;9(16):eade7622. https://doi.org/10.1126/sciadv.ade7622
Wang F, Wang J, Shen Y, Li H, Rausch WD, Huang X. Iron dyshomeostasis and ferroptosis: a new Alzheimer's disease hypothesis? Front Aging Neurosci. 2022;14. https://doi.org/10.3389/fnagi.2022.830569
Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998;273(21):12817-12826.
Garai K, Sahoo B, Kaushalya SK, Desai R, Maiti S. Zinc lowers amyloid-β toxicity by selectively precipitating aggregation intermediates. Biochem Int. 2007;46(37):10655-10663. https://doi.org/10.1021/bi700798b
Faller P. Copper and zinc binding to amyloid-β: coordination, dynamics, aggregation, reactivity and metal-ion transfer. ChemBioChem. 2009;10(18):2837-2845. https://doi.org/10.1002/cbic.200900321
Squitti R, Ghidoni R, Simonelli I, Ivanova ID, Colabufo NA, Zuin M, et al. Copper dyshomeostasis in Wilson disease and Alzheimer's disease as shown by serum and urine copper indicators. J Trace Elem Med Biol. 2018;45:181-188. https://linkinghub.elsevier.com/retrieve/pii/S0946672X17307903
Squitti R, Ghidoni R, Siotto M, Ventriglia M, Benussi L, Paterlini A, et al. Value of serum nonceruloplasmin copper for prediction of mild cognitive impairment conversion to Alzheimer disease: copper and MCI conversion. Ann Neurol. 2014;75(4):574-580. https://doi.org/10.1002/ana.24136
Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30(3):665-676. https://linkinghub.elsevier.com/retrieve/pii/S0896627301003178
Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron. 2008;59(1):43-55.
Yokoyama AS, Rutledge JC, Medici V. DNA methylation alterations in Alzheimer's disease. Environ Epigenetics. 2017;3(2):dvx008.
Sharma VK, Mehta V, Singh TG. Alzheimer's disorder: epigenetic connection and associated risk factors. Curr Neuropharmacol. 2020;18(8):740-753.
Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J Alzheimers Dis. 2004;6(4):367-377. discussion 443-449.
Rane JS, Bhaumik P, Panda D. Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro. J Alzheimers Dis. 2017;60(3):999-1014.
Zuo L, Hemmelgarn BT, Chuang CC, Best TM. The role of oxidative stress-induced epigenetic alterations in amyloid-β production in Alzheimer's disease. Oxid Med Cell Longev. 2015;2015:1-13. http://www.hindawi.com/journals/omcl/2015/604658/
Liu X, Jiao B, Shen L. The epigenetics of Alzheimer's disease: factors and therapeutic implications. Front Genet. 2018;9:579.
Li J, Wang S, Zhang S, Cheng D, Yang X, Wang Y, et al. Curcumin slows the progression of Alzheimer's disease by modulating mitochondrial stress responses via JMJD3-H3K27me3-BDNF axis. Am J Transl Res. 2021;13(12):13380-13393.
Van den Hove DL, Kompotis K, Lardenoije R, Kenis G, Mill J, Steinbusch HW, et al. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol Aging. 2014;35(4):731-745.
Tang M, Taghibiglou C. The mechanisms of action of curcumin in Alzheimer's disease. J Alzheimers Dis. 2017;58(4):1003-1016.
Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res. 2004;75(6):742-750.
Sparks S, Liu G, Robbins KJ, Lazo ND. Curcumin modulates the self-assembly of the islet amyloid polypeptide by disassembling α-helix. Biochem Biophys Res Commun. 2012;422(4):551-555.
Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892-5901.
Narlawar R, Pickhardt M, Leuchtenberger S, Baumann K, Krause S, Dyrks T, et al. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? ChemMedChem. 2008;3(1):165-172.
Oakley SS, Maina MB, Marshall KE, Al-Hilaly YK, Harrington CR, Wischik CM, et al. Tau filament self-assembly and structure: tau as a therapeutic target. Front Neurol. 2020;11:590754.
Kametani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease. Front Neurosci. 2018;12:25.
Lo Cascio F, Puangmalai N, Ellsworth A, Bucchieri F, Pace A, Palumbo Piccionello A, et al. Toxic tau oligomers modulated by novel curcumin derivatives. Sci Rep. 2019;9(1):19011.
Pradhan A, Mishra S, Surolia A, Panda D. C1 inhibits liquid-liquid phase separation and oligomerization of tau and protects Neuroblastoma cells against toxic tau oligomers. ACS Chem Nerosci. 2021;12(11):1989-2002.
Miyasaka T, Xie C, Yoshimura S, Shinzaki Y, Yoshina S, Kage-Nakadai E, et al. Curcumin improves tau-induced neuronal dysfunction of nematodes. Neurobiol Aging. 2016;39:69-81.
Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, et al. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem. 2013;288(6):4056-4065.
Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Mahanian M, et al. Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2006;10(1):1-7.
Li S, Hayden EY, Garcia VJ, Fuchs DT, Sheyn J, Daley DA, et al. Activated bone marrow-derived macrophages eradicate Alzheimer's-related Aβ42 oligomers and protect synapses. Front Immunol. 2020;11:49.
Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, et al. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci U S A. 2007;104(31):12849-12854. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1937555/
Gagliardi S, Franco V, Sorrentino S, Zucca S, Pandini C, Rota P, et al. Curcumin and novel synthetic analogs in cell-based studies of Alzheimer's disease. Front Pharmacol. 2018;9:1404.
Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST, et al. Incidence of Alzheimer's disease in a rural community in India: the indo-US study. Neurology. 2001;57(6):985-989.
Vas CJ, Pinto C, Panikker D, Noronha S, Deshpande N, Kulkarni L, et al. Prevalence of dementia in an urban Indian population. Int Psychogeriatr. 2001;13(4):439-450.
Ferrucci LM, Daniel CR, Kapur K, Chadha P, Shetty H, Graubard BI, et al. Measurement of spices and seasonings in India: opportunities for cancer epidemiology and prevention. Asian Pac J Cancer Prev. 2010;11(6):1621-1629.
Xu J, Zhou L, Weng Q, Xiao L, Li Q. Curcumin analogues attenuate Aβ25-35-induced oxidative stress in PC12 cells via Keap1/Nrf2/HO-1 signaling pathways. Chem Biol Interact. 2019;305:171-179.
Kim DS, Park SY, Kim JK. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci Lett. 2001;303(1):57-61.
Liu ZJ, Li ZH, Liu L, Tang WX, Wang Y, Dong MR, et al. Curcumin attenuates beta-amyloid-induced neuroinflammation via activation of peroxisome proliferator-activated receptor-gamma function in a rat model of Alzheimer's disease. Front Pharmacol. 2016;7:261.
Zhou J, Miao H, Li X, Hu Y, Sun H, Hou Y. Curcumin inhibits placental inflammation to ameliorate LPS-induced adverse pregnancy outcomes in mice via upregulation of phosphorylated Akt. Inflamm Res Off J Eur Histamine Res Soc Al. 2017;66(2):177-185.
Kang G, Kong PJ, Yuh YJ, Lim SY, Yim SV, Chun W, et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci. 2004;94(3):325-328.
ELBini-Dhouib I, Doghri R, Ellefi A, Degrach I, Srairi-Abid N, Gati A. Curcumin attenuated neurotoxicity in sporadic animal model of Alzheimer's disease. Mol Basel Switz. 2021;26(10):3011.
Di Meo F, Margarucci S, Galderisi U, Crispi S, Peluso G. Curcumin, gut microbiota, and neuroprotection. Nutrients. 2019;11(10):2426.
Perron NR, Brumaghim JL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys. 2009;53(2):75-100.
Zhang X, Tian Y, Li Z, Tian X, Sun H, Liu H, et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. J Am Chem Soc. 2013 Nov 6;135(44):16397-16409.
Abolaji AO, Fasae KD, Iwezor CE, Aschner M, Farombi EO. Curcumin attenuates copper-induced oxidative stress and neurotoxicity in Drosophila melanogaster. Toxicol Rep. 2020;7:261-268.
Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217(4558):408-414.
Ahmed T, Gilani AH. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol Biochem Behav. 2009;91(4):554-559.
Wahlström B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 1978;43(2):86-92.
Akinyemi AJ, Okonkwo PK, Faboya OA, Onikanni SA, Fadaka A, Olayide I, et al. Curcumin improves episodic memory in cadmium induced memory impairment through inhibition of acetylcholinesterase and adenosine deaminase activities in a rat model. Metab Brain Dis. 2017;32(1):87-95.
Khalil RM, Khedr NF. Curcumin protects against monosodium glutamate neurotoxicity and decreasing NMDA2B and mGluR5 expression in rat hippocampus. Neurosignals. 2016;24(1):81-87.
Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1-2):183-189.
Xu Y, Ku B, Tie L, Yao H, Jiang W, Ma X, et al. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res. 2006;1122(1):56-64.
Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014;28(4):579-585.
Pan R, Qiu S, Lu D-x, Dong J. Curcumin improves learning and memory ability and its neuroprotective mechanism in mice. Chin Med J (Engl). 2008;121(9):832-839.
Liu YL, Yang HP, Zhou XD, Gong L, Tang CL, Wang HJ. The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets. 2011;11(9):1098-1110.
Khor TO, Huang Y, Wu TY, Shu L, Lee J, Kong ANT. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem Pharmacol. 2011;82(9):1073-1078.
Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med Chem Lett. 2009;19(3):706-709. https://www.sciencedirect.com/science/article/pii/S0960894X08015515
Yun JM, Jialal I, Devaraj S. Epigenetic regulation of high glucose-induced proinflammatory cytokine production in monocytes by curcumin. J Nutr Biochem. 2011;22(5):450-458.
Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol. 2008;11(1):13-19.
Wu B, Yao X, Nie X, Xu R. Epigenetic reactivation of RANK in glioblastoma cells by curcumin: involvement of STAT3 inhibition. DNA Cell Biol. 2013;32(6):292-297.
Chen PT, Chen ZT, Hou WC, Yu LC, Chen RPY. Polyhydroxycurcuminoids but not curcumin upregulate neprilysin and can be applied to the prevention of Alzheimer's disease. Sci Rep. 2016;6:29760.
Bouyahya A, El Hachlafi N, Aanniz T, Bourais I, Mechchate H, Benali T, et al. Natural bioactive compounds targeting histone deacetylases in human cancers: recent updates. Mol Basel Switz. 2022;27(8):2568.
Pham TX, Lee J. Dietary regulation of histone acetylases and deacetylases for the prevention of metabolic diseases. Nutrients. 2012;4(12):1868-1886.
Lu X, Deng Y, Yu D, Cao H, Wang L, Liu L, et al. Histone acetyltransferase p300 mediates histone acetylation of PS1 and BACE1 in a cellular model of Alzheimer's disease. PloS One. 2014;9(7):e103067.
Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81-92.
Deng Y, Lu X, Wang L, Li T, Ding Y, Cao H, et al. Curcumin inhibits the AKT/NF-κB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line. AAPS J. 2014;16(4):649-657.
Tapia-Rojas C, Inestrosa NC. Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer's disease. Neural Regen Res. 2018;13(10):1705-1710.
Ashrafizadeh M, Ahmadi Z, Mohamamdinejad R, Yaribeygi H, Serban MC, Orafai HM, et al. Curcumin therapeutic modulation of the Wnt signaling pathway. Curr Pharm Biotechnol. 2020;21(11):1006-1015.
Ungurianu A, Zanfirescu A, Margină D. Regulation of gene expression through food-curcumin as a sirtuin activity modulator. Plants Basel Switz. 2022;11(13):1741.
Qu Z, Sun J, Zhang W, Yu J, Zhuang C. Transcription factor NRF2 as a promising therapeutic target for Alzheimer's disease. Free Radic Biol Med. 2020;159:87-102.
Momtazi AA, Derosa G, Maffioli P, Banach M, Sahebkar A. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther. 2016;20(4):335-345.
Patil SP, Tran N, Geekiyanage H, Liu L, Chan C. Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons. Neurosci Lett. 2013;554:121-125. https://www.sciencedirect.com/science/article/pii/S0304394013008240
Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr Dordr Neth. 2002;57(1):41-52.
Kim M, Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr Res Pract. 2010;4(3):191-195.
DiSilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012;11:79.
Cox KHM, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol Oxf Engl. 2015;29(5):642-651.
Baum L, Lam CWK, Cheung SKK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol. 2008;28(1):110-113.
Thota RN, Rosato JI, Dias CB, Burrows TL, Martins RN, Garg ML. Dietary supplementation with curcumin reduce circulating levels of glycogen synthase kinase-3β and islet amyloid polypeptide in adults with high risk of type 2 diabetes and Alzheimer's disease. Nutrients. 2020;12(4):1032. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230780/
Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther. 2012;4(5):43.
Hishikawa N, Takahashi Y, Amakusa Y, Tanno Y, Tuji Y, Niwa H, et al. Effects of turmeric on Alzheimer's disease with behavioral and psychological symptoms of dementia. Ayu. 2012;33(4):499-504.
Rainey-Smith SR, Brown BM, Sohrabi HR, Shah T, Goozee KG, Gupta VB, et al. Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr. 2016;115(12):2106-2113.
Small GW, Siddarth P, Li Z, Miller KJ, Ercoli L, Emerson ND, et al. Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: a double-blind, placebo-controlled 18-month trial. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2018;26(3):266-277.
Ge Y, Zeng F, Sun G, Peng K, Li X, Yu H, et al. Curcumin complex analogues as near-infrared fluorescent probes for monitoring all Aβ species in the early Alzheimer's disease model. ACS Chem Nerosci. 2021;12(19):3683-3689.
Rai H, Gupta S, Kumar S, Yang J, Singh SK, Ran C, et al. Near-infrared fluorescent probes as imaging and Theranostic modalities for amyloid-beta and tau aggregates in Alzheimer's disease. J Med Chem. 2022;65(13):8550-8595.